Vectus Biosystems Ltd

Drug discovery and development company Vectus Biosystems (ASX: VBS) has launched a $4.5 million capital raising to accelerate a phase 1b clinical trial of lead candidate VB0004 to treat fibrosis and hypertension. The raising will be conducted in two transactions, as a share placement to sophisticated investors and a share purchase plan to existing shareholders. […]

Fibrotic diseases specialist Vectus Biosystems (ASX: VBS) has confirmed that it will move to the next phase of testing of its lead drug for treating fibrosis and hypertension. In its September quarter report, the company says phase 1a clinical trials to date have established an “impressive safety profile” for the drug candidate VB0004, with consistent […]

Biotechnology company Vectus Biosystems (ASX: VBS) has announced the completion of its phase 1a study of lead drug candidate VB0004 to treat fibrosis and hypertension. It had been the company’s first in-human trial to evaluate the safety, tolerability, and pharmacokinetics of single and repeated doses of the drug in healthy volunteers, as well as patients […]

Ahead of enticing pharmaceutical partners, Vectus Biosystems (ASX: VBS) is confident that positive results will continue to flow from the ongoing phase 1 trial of its lead drug VB0004 which treats fibrosis and high blood pressure. The biotechnology company has developed its lead compound VB0004 as a treatment for hypertension (high blood pressure) and fibrosis […]